R. Samuel Herron from Goodwin Procter LLP Author Profile Page

R. Samuel Herron

Goodwin Procter LLP

ARTICLES
RANKINGS

Filter by:

Country(s)
United States
Topic(s)
Food, Drugs, Healthcare, Life Sciences Intellectual Property

Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA

25 Apr 2024 | United States

Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA

19 Mar 2024 | United States

Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation

11 Jan 2024 | United States

Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb)

31 Oct 2023 | United States

Genentech And Biogen File Joint Stipulation Of Dismissal In BPCIA Litigation Regarding Tocilizumab

27 Oct 2023 | United States

Update On mRNA Vaccine Patent Litigation

25 Sep 2023 | United States

FDA Issues Draft Guidance On Formal Meetings Between The FDA And Sponsors Or Applicants Of BsUFA Products And Classification Categories For Certain Supplements Under BsUFA III

17 Aug 2023 | United States

Regeneron v. Mylan – Update On Aflibercept BPCIA Litigation

13 Jun 2023 | United States

Genentech And Tanvex Reach Settlement In Principle In Trastuzumab BPCIA Litigation

24 Jan 2023 | United States

Genentech Voluntarily Recalls SUSVIMO (Ranibizumab)

02 Nov 2022 | United States

RELATED CONTENT

Contact Details

New York

New York

United States

© Mondaq® Ltd 1994 - 2024. All Rights Reserved.

Please to Mondaq or for unlimited free access and a complimentary news alert

|

|

|

|